Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Pharmacology|June 25, 2024
Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectivesYena Gan, Fenghao Shi, He Zhu, et al.
BMJ Open|October 18, 2023
Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysisHongbin Yi, Fenghao Shi, Zihao Wang, et al.
Journal of Comparative Effectiveness Research|March 18, 2026
Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in ChinaFenghao Shi, Shuhua Tan, Yamin Shu, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 28, 2024
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)Yixiao Zhu, Fenghao Shi, Huiting Lin, et al.
Immunotherapy|September 11, 2024
Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancerRuizhe Liu, Yijia Zhao, Fenghao Shi, et al.
BMC Medicine|March 5, 2025
Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18-40 years in ChinaRui Meng, Fenghao Shi, Baoming Zhang, et al.
Frontiers in Medicine|September 20, 2021
Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-AnalysisMingjun Rui, Zhengyang Fei, Yingcheng Wang, et al.
Iscience|March 9, 2026
Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancerYamin Shu, Fenghao Shi, Jinlin Xiong, et al.
Scientific Reports|April 14, 2025
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in ChinaCaifeng Jia, Sen Zhang, Jie Wang, et al.
Pageof 2